New Delhi, June 6 (IANS) A novel gene therapy for Alzheimer’s disease, which showed promise to protect the brain from damage and preserve cognitive function, has renewed hope for millions of patients with the neurodegenerative disease.
Worldwide, approximately 57 million people live with dementia, and Alzheimer’s disease is the most common cause, accounting for 60-70 per cent of cases.
Alzheimer’s occurs when abnormal proteins build up in the brain, leading to the death of brain cells and declines in cognitive function and memory.
While current treatments can manage symptoms of Alzheimer’s, the new gene therapy aims to halt or even reverse disease progression, said researchers from the University of California San Diego School of Medicine.
They noted that, unlike existing treatments for Alzheimer’s that target unhealthy protein deposits in the brain, the new approach could help address the root cause of Alzheimer’s disease by influencing the behaviour of brain cells themselves.
The study investigated the effect of hippocampal SynCav1 delivery in two distinct preclinical mice models.
The results, published in the journal Signal Transduction and Targeted Therapy, showed that delivering the treatment at the symptomatic stage of the disease preserved hippocampal-dependent memory — a critical aspect of cognitive function that is often impaired in Alzheimer’s patients.
Further, the finding stated that compared to healthy mice of the same age, the treated mice also had a similar pattern of gene expression. This suggests that the treatment has the potential to alter the behaviour of diseased cells to restore them to a healthier state.
“While multiple newly FDA-approved treatments focus on targeting amyloid-beta clearance in Alzheimer’s patients, the therapeutic value of SynCav1 lies in its ability to protect vulnerable neurons and augment cellular responses — mechanisms that differ from currently approved therapies,” said the researchers in the paper.
Due to the multitude of neurotoxicity in the Alzheimer’s brain, the team called for further studies to investigate SynCav1’s therapeutic role when combined with amyloid-targeted drugs to enhance clinical outcomes.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
